ROME (ITALPRESS) – Cardiovascular diseases are still responsible for about 40 percent of deaths in Italy. Diseases such as atrial fibrillation, heart failure and cardiac amyloidosis continue to represent a significant public health problem, requiring increasingly innovative and effective responses.Bayer Italy, a leading company in the field, devotes its ongoing commitment to the development of cutting-edge therapies, such as new molecules in the area of reduced and preserved ejection fraction decompensation, the recent advancement of a molecule for the treatment of transthyretin cardiac amyloidosis, and new research on gene therapies for heart failure. With more than a century of experience in the field, the company continues to invest in research, dedicating as much as 5.8 billion euros in 2023 so as to explore new frontiers in the treatment of heart disease.A key aspect is the crucial role of the patient within the care system. The concept of “proximity” proved to be central: Bayer Italy reiterated the importance of placing the patient at the center of any therapeutic strategy, with constant dialogue between institutions, physicians and patients themselves. Personalized support programs, such as the Patient Support Program (PSP), represent a virtuous model for improving therapeutic adherence, which often fails to be properly followed by people with chronic diseases, thus increasing their health risks.Collaboration between institutions, the medical community and patients has always been at the center of the discussions. Patients’ associations, considered by Bayer Italy to be key players in improving the health care system, play a key role in promoting dialogue, making it possible to improve the quality of care and make disease prevention and treatment strategies more effective. In light of this, among the initiatives promoted is the creation of TeraPiù, a free downloadable smartphone app designed with the aim of optimizing the management of medication intake by monitoring progress in the patient’s condition.World Heart Day 2024 thus reaffirmed the importance of an integrated approach that puts innovation and patients at the center. Only through close collaboration between research, physicians, and patients will it be possible to effectively address the challenges posed by cardiovascular disease, improving both the quality of care and the lives of patients.-photo press office Esperia Advocacy -(ITALPRESS).
